首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >DNA vaccination with a mutated p53 allele induces specific cytolytic T cells and protects against tumor cell growth and the formation of metastasis.
【24h】

DNA vaccination with a mutated p53 allele induces specific cytolytic T cells and protects against tumor cell growth and the formation of metastasis.

机译:用突变的p53等位基因进行DNA疫苗接种可诱导特异性的溶细胞性T细胞,并防止肿瘤细胞的生长和转移的形成。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: Genetic vaccination by expression plasmids that encode mutant p53 was conducted to characterize exogenously induced anti-tumoral immunity in mice. METHODS: Gene transfer was evaluated by reporter gene expression assays. The efficacy of genetic immunization was addressed by analysis of solid tumor outgrowth and the formation of metastases. Cell mediated immunity was determined by (51)Cr-release cytotoxicity assays and adoptive lymphocyte transfer experiments. RESULTS: Genetic vaccination resulted in a persistent protection against the growth and metastasis of transplanted tumor cells. Immunoprotection was based on the induction of cytolytic T cells (CTLs) able to recognize mutant but not wild type p53. Mice were not protected from tumor cell growth when the tumor cells expressed alternate p53 mutations or overexpressed wild type p53. No p53 specific humoral immune response was detected. T-lymphocyte transfer experiments demonstrated that resistance to tumor growth depended both on tumor size and a time-dependent induction of protective immunity. Small tumors (O < 0.4 cm(3)) went into remission or remained stable upon adoptive transfer of T-lymphocytes from mice immunized with mutant p53 DNA; larger tumors progressed. A time course of immunization was evaluated and showed that DNA vaccination must precede tumor cell inoculation in order to induce an efficient anti-tumoral response. CONCLUSION: DNA vaccination against the mutated form of p53 can elicit a specific adaptive immune response and has anti-tumoral activity. Tumor burden and the time necessary to acquire tumor immunity were recognized as critical parameters for immunization; however, tumors may evade specific immunotherapy.
机译:目的:通过编码突变型p53的表达质粒进行遗传接种,以表征小鼠中外源性诱导的抗肿瘤免疫。方法:通过报道基因表达分析评估基因转移。通过分析实体瘤的生长和转移的形成来解决基因免疫的有效性。细胞介导的免疫力通过(51)Cr释放细胞毒性测定和过继性淋巴细胞转移实验确定。结果:基因疫苗接种对移植肿瘤细胞的生长和转移具有持久的保护作用。免疫保护作用基于能够识别突变型而非野生型p53的溶细胞性T细胞(CTL)的诱导。当肿瘤细胞表达交替的p53突变或过表达的野生型p53时,小鼠不受肿瘤细胞生长的保护。没有检测到p53特异性体液免疫反应。 T淋巴细胞转移实验表明,对肿瘤生长的抗性既取决于肿瘤的大小,又取决于保护性免疫的时间依赖性。从突变p53 DNA免疫的小鼠过继转移T淋巴细胞后,小肿瘤(O <0.4 cm(3))缓解或保持稳定。较大的肿瘤进展。评估了免疫的时间过程,结果表明必须在肿瘤细胞接种之前进行DNA疫苗接种才能诱导有效的抗肿瘤反应。结论:针对p53突变形式的DNA疫苗可以引起特异性的适应性免疫反应,并具有抗肿瘤活性。肿瘤负荷和获得肿瘤免疫所需的时间被认为是免疫的关键参数;但是,肿瘤可能会逃避特异性免疫治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号